Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

This article was originally published in RPM Report

Executive Summary

It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.

You may also be interested in...



Braving The PPAR Storm, Zydus Cadila Says Its Potential Blockbuster Is Approved In India

Zydus Cadila scores a regulatory approval in India for Lipaglyn, a PPAR alpha/gamma dual agonist, but in a class known for cardiovascular risks the product will likely be under close scrutiny.

Which Came First? Alogliptin Avoids Possible Exclusivity Dispute

An unusual footnote in FDA’s approval letter for Takeda’s long-delayed diabetes medicine means that the company won’t have to worry about losing five-year exclusivity on the molecule.

Diabetes Drug Development: Seeing Light In The Dark Ages?

Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel